Cardiovascular drugs and erectile dysfunction - a symmetry analysis

Lotte Rasmussen, Jesper Hallas, Kenneth Grønkjaer Madsen, Anton Pottegård

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

AIM: Erectile dysfunction is a common problem among patients with cardiovascular diseases and the influence of cardiovascular drugs is much debated. The aim of this study was to evaluate the short term potential for different cardiovascular drugs to affect the risk of being prescribed a drug against erectile dysfunction.

METHODS: We employed a symmetry analysis design and included all Danish male individuals born before 1950 who filled their first ever prescription for a cardiovascular drug and a 5-phosphodiesterase inhibitor within a 6 month interval during 2002-2012. If the cardiovascular drug induces erectile dysfunction, this would manifest as a non-symmetrical distribution of subjects being prescribed the cardiovascular drug first vs. persons following the opposite pattern. Furthermore, we calculated the number of patients needed to treat for one additional patient to be treated for erectile dysfunction (NNTH).

RESULTS: We identified 20 072 males with a median age of 64 years (IQR 60-70) who initiated a cardiovascular drug and a 5-phosphodiesterase inhibitor within a 6 month interval. Sequence ratios showed minor asymmetry in prescription orders after adjustment for trends in prescribing. This asymmetry was most profound for thiazides (1.28, 95% CI 1.20, 1.38), calcium channel blockers (1.29, 95% CI 1.21, 1.38) and ACE inhibitors (1.29, 95% CI 1.21, 1.37), suggesting a small liability of these drugs to provoke erectile dysfunction. NNTH values were generally large, in the range of 330-6400, corresponding to small absolute effects.

CONCLUSION: Our study does not suggest that cardiovascular drugs strongly affect the risk of being prescribed a drug against erectile dysfunction on a short term basis.

OriginalsprogEngelsk
TidsskriftBritish Journal of Clinical Pharmacology
Vol/bind80
Udgave nummer5
Sider (fra-til)1219-1223
ISSN0306-5251
DOI
StatusUdgivet - 10. jun. 2015

Fingeraftryk

Prescriptions
Pharmaceutical Preparations
Numbers Needed To Treat

Citer dette

@article{37340e1926774e3b82529c6ec830531d,
title = "Cardiovascular drugs and erectile dysfunction - a symmetry analysis",
abstract = "AIM: Erectile dysfunction is a common problem among patients with cardiovascular diseases and the influence of cardiovascular drugs is much debated. The aim of this study was to evaluate the short term potential for different cardiovascular drugs to affect the risk of being prescribed a drug against erectile dysfunction.METHODS: We employed a symmetry analysis design and included all Danish male individuals born before 1950 who filled their first ever prescription for a cardiovascular drug and a 5-phosphodiesterase inhibitor within a 6 month interval during 2002-2012. If the cardiovascular drug induces erectile dysfunction, this would manifest as a non-symmetrical distribution of subjects being prescribed the cardiovascular drug first vs. persons following the opposite pattern. Furthermore, we calculated the number of patients needed to treat for one additional patient to be treated for erectile dysfunction (NNTH).RESULTS: We identified 20 072 males with a median age of 64 years (IQR 60-70) who initiated a cardiovascular drug and a 5-phosphodiesterase inhibitor within a 6 month interval. Sequence ratios showed minor asymmetry in prescription orders after adjustment for trends in prescribing. This asymmetry was most profound for thiazides (1.28, 95{\%} CI 1.20, 1.38), calcium channel blockers (1.29, 95{\%} CI 1.21, 1.38) and ACE inhibitors (1.29, 95{\%} CI 1.21, 1.37), suggesting a small liability of these drugs to provoke erectile dysfunction. NNTH values were generally large, in the range of 330-6400, corresponding to small absolute effects.CONCLUSION: Our study does not suggest that cardiovascular drugs strongly affect the risk of being prescribed a drug against erectile dysfunction on a short term basis.",
author = "Lotte Rasmussen and Jesper Hallas and Madsen, {Kenneth Gr{\o}nkjaer} and Anton Potteg{\aa}rd",
note = "{\circledC} 2015 The British Pharmacological Society.",
year = "2015",
month = "6",
day = "10",
doi = "10.1111/bcp.12696",
language = "English",
volume = "80",
pages = "1219--1223",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "5",

}

Cardiovascular drugs and erectile dysfunction - a symmetry analysis. / Rasmussen, Lotte; Hallas, Jesper; Madsen, Kenneth Grønkjaer; Pottegård, Anton.

I: British Journal of Clinical Pharmacology, Bind 80, Nr. 5, 10.06.2015, s. 1219-1223.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Cardiovascular drugs and erectile dysfunction - a symmetry analysis

AU - Rasmussen, Lotte

AU - Hallas, Jesper

AU - Madsen, Kenneth Grønkjaer

AU - Pottegård, Anton

N1 - © 2015 The British Pharmacological Society.

PY - 2015/6/10

Y1 - 2015/6/10

N2 - AIM: Erectile dysfunction is a common problem among patients with cardiovascular diseases and the influence of cardiovascular drugs is much debated. The aim of this study was to evaluate the short term potential for different cardiovascular drugs to affect the risk of being prescribed a drug against erectile dysfunction.METHODS: We employed a symmetry analysis design and included all Danish male individuals born before 1950 who filled their first ever prescription for a cardiovascular drug and a 5-phosphodiesterase inhibitor within a 6 month interval during 2002-2012. If the cardiovascular drug induces erectile dysfunction, this would manifest as a non-symmetrical distribution of subjects being prescribed the cardiovascular drug first vs. persons following the opposite pattern. Furthermore, we calculated the number of patients needed to treat for one additional patient to be treated for erectile dysfunction (NNTH).RESULTS: We identified 20 072 males with a median age of 64 years (IQR 60-70) who initiated a cardiovascular drug and a 5-phosphodiesterase inhibitor within a 6 month interval. Sequence ratios showed minor asymmetry in prescription orders after adjustment for trends in prescribing. This asymmetry was most profound for thiazides (1.28, 95% CI 1.20, 1.38), calcium channel blockers (1.29, 95% CI 1.21, 1.38) and ACE inhibitors (1.29, 95% CI 1.21, 1.37), suggesting a small liability of these drugs to provoke erectile dysfunction. NNTH values were generally large, in the range of 330-6400, corresponding to small absolute effects.CONCLUSION: Our study does not suggest that cardiovascular drugs strongly affect the risk of being prescribed a drug against erectile dysfunction on a short term basis.

AB - AIM: Erectile dysfunction is a common problem among patients with cardiovascular diseases and the influence of cardiovascular drugs is much debated. The aim of this study was to evaluate the short term potential for different cardiovascular drugs to affect the risk of being prescribed a drug against erectile dysfunction.METHODS: We employed a symmetry analysis design and included all Danish male individuals born before 1950 who filled their first ever prescription for a cardiovascular drug and a 5-phosphodiesterase inhibitor within a 6 month interval during 2002-2012. If the cardiovascular drug induces erectile dysfunction, this would manifest as a non-symmetrical distribution of subjects being prescribed the cardiovascular drug first vs. persons following the opposite pattern. Furthermore, we calculated the number of patients needed to treat for one additional patient to be treated for erectile dysfunction (NNTH).RESULTS: We identified 20 072 males with a median age of 64 years (IQR 60-70) who initiated a cardiovascular drug and a 5-phosphodiesterase inhibitor within a 6 month interval. Sequence ratios showed minor asymmetry in prescription orders after adjustment for trends in prescribing. This asymmetry was most profound for thiazides (1.28, 95% CI 1.20, 1.38), calcium channel blockers (1.29, 95% CI 1.21, 1.38) and ACE inhibitors (1.29, 95% CI 1.21, 1.37), suggesting a small liability of these drugs to provoke erectile dysfunction. NNTH values were generally large, in the range of 330-6400, corresponding to small absolute effects.CONCLUSION: Our study does not suggest that cardiovascular drugs strongly affect the risk of being prescribed a drug against erectile dysfunction on a short term basis.

U2 - 10.1111/bcp.12696

DO - 10.1111/bcp.12696

M3 - Journal article

C2 - 26094913

VL - 80

SP - 1219

EP - 1223

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 5

ER -